

(augmentation pressure) of the arterial waveform, expressed as a percentage of the pulse pressure (Figure 1)¹⁰⁻¹². Normally, arterial elasticity converts pulsatile flow to a more constant flow, mainly in the proximal vessels¹³. Blood vessels with high compliance (i.e., low stiffness) experience only small systolic pressure increases with a relatively large increase in volume. Conversely, overly stiff central vessels cannot absorb more than a small fraction of each cardiac stroke volume without a substantial increase in pressure. Individuals with stiff central arteries (e.g., hypertensive or elderly persons)^{14,15} typically have relatively high systolic and pulse pressures and low diastolic pressure¹¹, with increasing AI. Endothelial function testing reflects NO production in medium-small arteries. Nitric oxide is constitutionally expressed in normal endothelium and has vasodilatory, antiinflammatory, and antithrombotic properties. Peripheral endothelial function may be measured by a non-invasive plethysmograph (EndoPAT 2000; Itamar Medical, Caesarea, Israel), assessing post-occlusion brachial artery flow-mediated dilatation (FMD), which reflects endothelium-dependent reperfusion hyperemia¹⁶⁻²².

In a previous study, we demonstrated peripheral endothelial dysfunction in patients with IPAH, scleroderma-PAH, and CTEPH and preserved endothelial function in PAH in patients with congenital heart disease associated PAH²³.

The aim of our study was to investigate arterial stiffness in IPAH and scleroderma-PAH and its association with endothelial function. We hypothesized that patients with scleroderma will have increased peripheral arterial stiffness, compared to healthy controls and patients with IPAH.

MATERIALS AND METHODS

Study participants. Our study was prospective and cross-sectional. The study group included patients with IPAH or scleroderma associated PAH. The control groups consisted of scleroderma patients with normal pulmonary pressure and healthy controls. Medication was stable for 3 months

prior to enrollment until the end of the study period. Exclusion criteria were diabetes, ischemic heart disease, cerebrovascular event, obstructive sleep apnea syndrome, renal failure, or systemic hypertension or concurrent medication with nitrates, alpha/beta blockers, and angiotensin-converting enzyme inhibitors. Obstructive sleep apnea was excluded due to a reversible endothelial dysfunction in this syndrome²⁴.

Study protocol. All subjects underwent a full medical history, function class grading (New York Heart Association, NYHA), and physical examination. Laboratory assessment included pulmonary function tests, oxygen saturation (pulse oximetry), carbon monoxide diffusion capacity (DLCO), 6-min walk test, and transthoracic echocardiography. Twenty-four patients had undergone cardiac catheterization, and data on mean pulmonary pressure, cardiac index, and pulmonary vascular resistance were obtained from their records.

Pulse wave analysis was performed in the morning under stable conditions, after an overnight fast. Subjects were asked to refrain from smoking and from drinking alcohol or caffeinated drinks for 12 h. During testing, subjects were seated on a comfortable chair with both hands placed at the level of the heart. The Endo-PAT 2000 device (Itamar Medical) was used to obtain a beat-to-beat plethysmographic recording of the finger arterial pulse-wave amplitude (PWA). A pneumatic probe was placed on the index finger of each hand to record peripheral arterial tone (PAT). Following a 20-min equilibrium period (20°C constant temperature), baseline measurements were acquired over 5 min at rest. For AI measurement, the baseline signal from the rest period was used. AI was defined as the difference between the first (P1) and the second (P2) peaks of the arterial waveform, expressed as a percentage of the pulse pressure [(P2 - P1)/P1; Figure 1]. For endothelial dysfunction assessment, post-brachial artery occlusion wave was used. Occlusion was induced by inflating the cuff on the upper arm to 50 mm Hg above systolic pressure for 5 min and then releasing it to induce reactive (flow-mediated) hyperemia. The post-obstructive PWA was measured starting 90 seconds after cuff deflation, for 210 seconds. Endothelial function was calculated as the ratio between the average post-obstruction PWA and the average 3-minute baseline PWA, corrected for systemic changes and baseline signal amplitude. Both signals (AI and PAT) were analyzed with a computerized automated algorithm by the Endo-Pat 2000 system. Absolute endothelial dysfunction was defined as a PAT ratio of less than 1.67^{25,26}. This FMD test has been used and compared with other methods¹⁶⁻²² in many previous studies^{17,18,25,26}. Figure 2 presents examples of the normal and pathological (reactive hyperemia) pictures using the Endo-PAT 2000 device. The use of fingertip tonometry was validated previously and shown to be in close correlation with radial tonometry^{12,27,28}.




Figure 1. Augmentation index (AI) is the difference between the first (P1) and second (P2) peaks of the arterial waveform, expressed as a percentage of the pulse pressure [(P2 - P1)/P1]. A. Pulse wave of a young adult with low arterial stiffness (AI = -30%). B. An elderly adult: high arterial stiffness (AI = 30%).




Figure 2. EndoPAT 2000 signals. Normal (A) and abnormal (B) hyperemic response.

Our study was approved by the institutional review board of our center. All subjects signed an informed consent form to participate in the study.

Statistical analysis. Descriptive statistics were calculated for each group. Differences among the patient groups were analyzed by analysis of variance (ANOVA) and chi-squared test (contingency tables), and differences between patients and controls were analyzed by ANOVA. For post hoc analysis, the Scheffe test was used. A p value < 0.05 was considered significant. The Statistical Package for Social Sciences (SPSS Corp., version 15) was used for data handling and analysis.

RESULTS

Thirty-eight patients (28 IPAH; 10 scleroderma-PAH) and 21 control subjects (13 healthy; 8 scleroderma) participated in the study (Table 1). Mean pulmonary pressure was 70.5 ± 21.6 mm Hg in the IPAH group and 69.3 mm Hg in the

scleroderma associated PAH and normal in controls (Table 1). Five patients were treated with epoprostenol, 7 with treprostenil, 7 with bosentan, 12 with other selective endothelin receptor blockers, 11 with sildenafil, and 7 with calcium channel blockers. Age, body mass index (BMI), and NYHA classification were similar in all patient groups. Comparison of the PAH patients with the control subjects yielded a statistically significant difference in NYHA class, baseline oxygen saturation, and DLCO. Where available, patients in the PAH groups had higher pulmonary artery pressures than the non-PAH scleroderma controls; none of the healthy controls had PA catheterization data for comparison.

Mean distance on the 6-min walk test was 399 ± 118 m in the IPAH group or 315 ± 77 m in the scleroderma-PAH (p = 0.044) group, although pulmonary hemodynamics, DLCO, and exercise desaturation were similar in both the PAH groups.

Arterial stiffness — augmentation index. AI was 10.5% ± 19.6% in healthy controls and 9.0% ± 21.5% in the IPAH group. In the scleroderma group, AI was twice as high: in the scleroderma-PAH group (20.1% ± 19.1%; nonsignificant) and 24.4 ± 18.9% in the scleroderma control group (nonsignificant vs healthy controls; Table 1, Figure 3). AI was positively correlated with age (Figure 4; r = 0.597; p = 0.001), but was not associated with the presence of PAH or other pulmonary or hemodynamic measurements.

Brachial artery endothelial function. As we have reported previously, peripheral arterial endothelial function was sig-

Table 1. Clinical and epidemiologic characteristics of patients with pulmonary arterial hypertension (PAH) and controls.

	Healthy Controls	Idiopathic PAH	Scleroderma-PAH	Scleroderma-only Control	p (for patient groups)
Characteristics					
No.	13	28	10	8	
M:F	2:11	8:20	2:8	1:7	0.743
Age, yrs	46.0 ± 14.1	51.9 ± 13.6	54.3 ± 14.2	58.5 ± 12.1	0.632
BMI, kg/m ²	24.3 ± 3.6	26.3 ± 6.7	23.7 ± 4.5	25.9 ± 4.1	0.259
NYHA	1.0	1.9 ± 0.7**	2.2 ± 0.6**	1.0	0.184
I, n (%)	13	7 (24)	1 (10)	8	
II, n (%)		17 (61)	6 (61)		
III-IV, n (%)		4 (14)	3 (30)		
Clinical findings					
Pulse/min	73.5 ± 10.6	78.2 ± 12.0	81.2 ± 12.6	83.2 ± 7.8*	0.509
BL sat, %	97.5 ± 1.4	94.3 ± 5.1*	94.2 ± 5.5*	98.3 ± 2.7	0.964
6MWT, m	512 ± 35	399 ± 118	315 ± 77**	451 ± 53	0.044
6MWT sat, %	98.3 ± 0.8	89.8 ± 9.1**	85.0 ± 12.8**	97.8 ± 2.1	0.208
DLCO, %	98.5 ± 3.5	58.1 ± 20.3**	43.0 ± 28.1**	74.0 ± 28.8	0.079
PPR, mm Hg	23.0 ± 4.2	70.5 ± 21.6**	69.3 ± 20.1**	31.2 ± 11.2	0.882
CO, l/min		4.3 ± 1.4	4.4 ± 1.5	5.9 ± 2.3	0.884
PVR, MPa·s/m ³		11.4 ± 5.6	14.9 ± 5.7	2.8 ± 0.7	0.209
PAT ratio	2.20 ± 0.25	1.84 ± 0.51*	1.66 ± 0.66*	2.03 ± 0.38	0.380
AI, %	10.5 ± 19.6	9.0 ± 21.5	20.1 ± 19.1	24.4 ± 18.9	0.199

* p < 0.05 compared to control; ** p < 0.01 compared to control. BMI: body mass index; NYHA: New York Heart Association; BL sat: baseline oxygen saturation; PPR: mean pulmonary pressure; CO: cardiac output. DLCO: carbon monoxide diffusion capacity; PVR: pulmonary vascular resistance in pascal seconds/m³; 6MWT: 6-minute walk test; PAT: peripheral arterial tone; AI: augmentation index.




Figure 3. Augmentation index in all study groups (nonsignificant). Scl: scleroderma; IPAH: idiopathic pulmonary arterial hypertension.




Figure 4. Augmentation index and age in study subjects ($r = 0.597$; $p = 0.001$).

nificantly disturbed in IPAH (1.84 ± 0.51 ; $p = 0.023$) and in scleroderma-PAH (1.66 ± 0.66 ; $p = 0.014$) versus controls (PAT ratio: 2.20 ± 0.25). The scleroderma control group had similar PAT ratio (2.03 ± 0.38) as the healthy control group (Table 1)²³. There was no correlation between AI and endothelial dysfunction.

Scleroderma with and without PAH. The patients with scleroderma and PAH were compared to age- and BMI-matched control subjects with scleroderma and normal pulmonary arterial pressure. The pulmonary hypertension group had

worse clinical and cardiopulmonary measurements and had disturbed endothelial function (PAT ratio 1.66 ± 0.66 vs 2.20 ± 0.25 ; $p = 0.014$; Table 1). AI was similarly high in both groups ($20.1\% \pm 19.1\%$ and $24.4\% \pm 18.9\%$, vs $10.5\% \pm 19.6\%$ in healthy controls; nonsignificant; Table 1, Figure 3).

DISCUSSION

In our study, 28 patients with IPAH, 10 with scleroderma-PAH, and 21 control subjects were assessed for arterial stiffness and endothelial dysfunction. Our analysis yielded 3 main findings: (1) peripheral arterial stiffness is normal in PAH and seems not to be correlated with PAH per se; (2) arterial stiffness has a tendency to be higher in patients with scleroderma, unrelated to the presence of PAH; (3) peripheral endothelial function is disturbed in IPAH and in scleroderma associated PAH.

Arterial stiffness is largely the result of progressive elastic fiber degeneration, mainly collagen and elastin²⁹, but the endothelial³⁰ and arterial wall smooth-muscle bulk and tone³¹ also play a role. Previous studies have shown that genetic polymorphisms of fibrillin 1³², angiotensin II type 1 receptor³³, and endothelin receptor gene are related to arterial stiffness. The normal pulmonary circulation exhibits very little wave reflection⁹, optimizing the right ventricular-pulmonary artery coupling³⁴. The pulmonary artery reflected wave is increased in conditions such as IPAH^{8,9} and CTEPH⁹. However, since increased reflected wave has been also reported in left heart failure^{35,36}, one can speculate that the increased reflected wave seen in pulmonary circulation^{9,37} is secondary to the increased pulmonary arterial pressure, and is not a primary vascular wall abnormality per se. To our knowledge, our study is the first to report preserved systemic arterial stiffness in IPAH, as with normal age-dependent AI increase (15, Figure 4). In our cohort, the scleroderma group showed a trend towards increased AI, unrelated to the presence or absence of PAH (Table 1). This trend did not reach statistical significance — most probably due to the small sample size. An increased arterial stiffness in patients with scleroderma has been reported³⁸⁻⁴⁰. The increase in arterial stiffness has been shown to increase with the degree of endothelial inflammation soluble endothelial adhesion molecules, E-selectin, and soluble vascular cellular adhesion molecule-1, and is unrelated to endothelial dysfunction⁴⁰.

Our previous findings²³ of peripheral endothelial dysfunction in IPAH and scleroderma associated PAH and now the increased AI in scleroderma (Table 1) may indicate systemic endothelial involvement in scleroderma-PAH that is different from that seen in IPAH. Support for such systemic vascular involvement in PAH was provided by Hughes, *et al*⁴¹, who reported a significant reduction in brachial artery dilatation in patients with IPAH and their relatives, and in patients with systemic sclerosis with PAH. Additionally,

Bull, *et al*⁴² observed a higher rate of circulating endothelial cells in patients with pulmonary hypertension, which was correlated with pulmonary pressure. Affected patients had higher values of CD36, a marker of microvascular origin, and of E-selectin, a marker of endothelial cell activation. The systemic involvement might be related primarily to the disease pathobiology, or mediated by a high activity of circulatory mediators in PAH such as proinflammatory cytokines⁴³, alterations in metabolic pathways of serotonin⁴⁴, prothrombotic abnormalities^{5,45,46}, or hypoxia and sympathetic overactivity⁴⁷.

AI was unrelated to endothelial dysfunction in our analysis. This finding is not surprising, since AI reflects arterial wall elasticity of large and medium size arteries¹³, while the hyperemic test assesses the endothelium for its ability to produce NO in the medium-small arteries^{22,40}. Our findings are in agreement with Andersen, *et al*⁴⁰, who failed to show association between AI and endothelial dysfunction in patients with scleroderma.

One confounding factor in our data was the use of PAH-specific drugs that may also modulate systemic endothelial function. To reduce variability, we measured endothelial dysfunction only in patients on stable regimens for 3 months prior to the study. Ethically, we could not stop the medication prior to the study. Nevertheless, the treatment regimen apparently had no effect on the reflected wave or the PAT signal (baseline or ratio; data not shown).

Our study demonstrates a trend towards increased arterial stiffness in patients with scleroderma, unrelated to their pulmonary pressure, and preserved arterial stiffness in those with IPAH with concomitant endothelial dysfunction. Arterial elasticity is unrelated to endothelial dysfunction *per se*. Since large vessels contribute to elasticity while medium and small vessels contribute to endothelial function, our study suggests that there is divergence in the location and nature of systemic vascular dysfunction between patients with scleroderma-PAH compared to those with IPAH.

REFERENCES

- Rubin LW. Pulmonary hypertension. *Proc Am Thorac Soc* 2006;3:111-5.
- Humbert M, Stibon O, Simonneau G. Treatment of pulmonary arterial hypertension. *N Engl J Med* 2004;351:1425-36.
- Runo JR, Loyd JE. Primary pulmonary hypertension. *Lancet* 2003;361:1533-44.
- Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. *N Engl J Med* 1995;333:214-21.
- Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. *N Engl J Med* 1992;327:70-5.
- Humbert M, Morrell N, Archer S, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. *J Am Coll Cardiol* 2004;43:S13-24.
- Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. *Circulation* 2004;109:159-65.
- Laskey WK, Ferrari VA, Palevsky HI, Kussmaul WG. Pulmonary artery hemodynamics in primary pulmonary hypertension. *J Am Coll Cardiol* 1993;21:406-12.
- Castelain V, Hervé P, Lecarpentier Y, Duroux P, Simonneau G, Chemla D. Pulmonary artery pulse pressure and wave reflection in chronic pulmonary thromboembolism and primary pulmonary hypertension. *J Am Coll Cardiol* 2001;37:1085-92.
- Munir S, Guilcher A, Kamallesh T, et al. Peripheral augmentation index defines the relationship between central and peripheral pulse pressure. *Hypertension* 2008;51:112-8.
- Izzo JL Jr, Shykoff BE. Arterial stiffness: clinical relevance, measurement, and treatment. *Rev Cardiovasc Med* 2001;2:29-40.
- Haller MJ, Silverstein JH, Shuster JJ. Correlation between radial artery tonometry- and fingertip tonometry-derived augmentation index in children with type 1 diabetes. *Diab Vasc Dis Res* 2007;4:66.
- Izzo JL Jr. Hypertension in the elderly: a pathophysiologic approach to therapy. *J Am Geriatr Soc* 1982;30:352-9.
- Cheng KS, Baker CR, Hamilton G, Hoeks AP, Seifalian AM. Arterial elastic properties and cardiovascular risk/event. *Eur J Vasc Endovasc Surg* 2002;24:383-97.
- McVeigh GE, Bratteli CW, Morgan DJ, et al. Age related abnormalities in arterial compliance identified by pressure pulse contour analysis. Aging and arterial compliance. *Hypertension* 1999;33:1392-8.
- Bonetti PO, Pumper GM, Higano ST, Holmes DR, Kuvin JT, Lerman A. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. *J Am Coll Cardiol* 2004;44:2137-41.
- Kuvin JT, Patel AR, Sliney KA, et al. Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. *Am Heart J* 2003;146:168-74.
- Bonetti PO, Barsness GW, Keelen PC, et al. Enhanced external counterpulsation improved endothelial function in patients with symptomatic coronary artery disease. *J Am Coll Cardiol* 2003;41:176-8.
- Kuvin J, Patel A, Karas R. Need for standardization of non-invasive assessment of vascular endothelial function. *Am Heart J* 2001;144:327-8.
- Kuvin J, Patel A, Sliney K, et al. Peripheral vascular endothelial function testing as a non-invasive indicator of coronary artery disease. *Am J Coll Cardiol* 2001;38:1843-9.
- Schroeter H, Heiss C, Balzer J, et al. Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans. *Proc Nat Acad Sci USA* 2006;103:1024-9.
- Meredith IT, Currie KE, Anderson TJ, Roddy MA, Ganz P, Vreager MA. Postischemic vasodilation in human forearm is dependent on endothelium-derived nitric oxide. *Am J Physiol* 1996;270:H1435-40.
- Peled N, Bendayan D, Shitrit D, Fox B, Yehoshua L, Kramer MR. Peripheral endothelial dysfunction in patients with pulmonary hypertension. *Respir Med* 2008;102:1631-5.
- Itzhaki S, Dorchin H, Clark G, Lavie L, Lavie P, Pillar G. The effects of 1-year treatment with a herbist mandibular advancement splint on obstructive sleep apnea, oxidative stress, and endothelial function. *Chest* 2007;131:740-9.
- Yinon D, Lowenstein L, Suraya S, et al. Pre-eclampsia is associated with sleep-disordered breathing and endothelial dysfunction. *Eur Respir J* 2006;27:328-33.
- Itzhaki S, Lavie L, Pillar G, Tal G, Lavie P. Endothelial dysfunction in obstructive sleep apnea measured by peripheral arterial tone response in the finger to reactive hyperemia. *Sleep* 2005;28:594-600.
- Haller MJ, Samyn M, Nichols WW, et al. Radial artery tonometry demonstrates arterial stiffness in children with type 1 diabetes. *Diabetes Care* 2004;27:2911-7.

28. Haller MJ, Stein J, Shuster J, et al. Peripheral artery tonometry demonstrates altered endothelial function in children with type 1 diabetes. *Pediatr Diabetes* 2007;8:193-8.
29. Oliver JJ, Webb DJ. Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. *Arterioscler Thromb Vasc Biol* 2003;23:554-66.
30. Wilkinson IB, Qasem A, McEniery CM, Avolio AP, Cockcroft JR. Nitric oxide regulates local arterial distensibility in vivo. *Circulation* 2002;105:213-7.
31. Bank AJ, Kalsner DR, Rajala S, Cheng A. In vivo human brachial artery elastic mechanics: effects of smooth muscle relaxation. *Circulation* 1999;100:41-7.
32. Medley TL, Cole TJ, Gatzka CD, Wang WY, Dart AM, Kingwell BA. Fibrillin-1 genotype is associated with aortic stiffness and disease severity in patients with coronary artery disease. *Circulation* 2002;105:810-5.
33. Lajemi M, Labat C, Gautier S, et al. Angiotensin II type 1 receptor-153A/G and 1166A/C gene polymorphisms and increase in aortic stiffness with age in hypertensive subjects. *J Hypertens* 2001;19:407-13.
34. Ha B, Lucas CL, Henry WH, Frantz EG, Ferreira JI, Wilcox BR. Effects of chronically elevated pulmonary arterial pressure and flow on right ventricular afterload. *Am J Physiol* 1994;267:H155-65.
35. Yin FCP, Ting CT. Wave reflection in pulmonary hypertension. In: Wier EK, Archer SL, Reeves JT, editors. *The diagnosis and treatment of pulmonary hypertension*. Mount Kisco, NY: Futura; 1992:111-23.
36. Kussmaul WG, Noordergraaf A, Laskey WK. Right ventricular pulmonary interactions. *Ann Biomed Eng* 1992;20:63-80.
37. Karamanoglu M, McGoon M, Frantz RP, et al. Right ventricular pressure waveform and wave reflection analysis in patients with pulmonary arterial hypertension. *Chest* 2007;132:37-43.
38. Constans J, Germain C, Gosse P, et al. Arterial stiffness predicts severe progression in systemic sclerosis: the ERAMS study. *J Hypertens* 2007;25:1900-6.
39. Moysakakis I, Gialafos E, Vassiliou V, et al. Aortic stiffness in systemic sclerosis is increased independently of the extent of skin involvement. *Rheumatology* 2005;44:251-4.
40. Andersen GN, Mincheva-Nilsson L, Kazzam E, et al. Assessment of vascular function in systemic sclerosis: indications of the development of nitrate tolerance as a result of enhanced endothelial nitric oxide production. *Arthritis Rheum* 2002;46:1324-32.
41. Hughes R, Tong J, Oats C, Lordan J, Corris PA. Evidence for systemic endothelial dysfunction in patients and first-order relatives with pulmonary hypertension. *Chest* 2005;128:617S.
42. Bull TM, Golpon H, Heibel RP, et al. Circulating endothelial cells in pulmonary hypertension. *Thromb Haemost* 2003;90:698-703.
43. Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. *Eur Respir J* 2003;22:358-63.
44. Eddahibi S, Humbert M, Fadel E, et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. *J Clin Invest* 2001;108:1141-50.
45. Friedman R, Mears JG, Barst RJ. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. *Circulation* 1997;96:2782-4.
46. Eisenberg PR, Lucore C, Kaufman L, Sobel BE, Jaffe AS, Rich S. Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. *Circulation* 1990;82:841-7.
47. Velez-Roa S, Ciarka A, Najem B, Vachiere JL, Naeije R, Van de Borne P. Increased sympathetic nerve activity in pulmonary hypertension. *Circulation* 2004;110:1308-12.